Start Date
December 2, 2024
Primary Completion Date
January 31, 2028
Study Completion Date
July 31, 2028
LN-144
A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-144), followed by IL-2.
Cyclophosphamide
Given by IV.
Mesna
Given by IV.
Fludarabine
Given by IV.
Interleukin-2 (IL-2)
Given by IV.
Pembrolizumab
Given by IV.
Collaborators (1)
Iovance Biotherapeutics, Inc.
INDUSTRY
James Isaacs, MD
OTHER